We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Net Medical Xpress Solutions Inc (PK) | USOTC:NMXS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0119 | 0.0083 | 0.012 | 0.00 | 12:18:04 |
|
UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
Washington, DC 20549 |
|
|
FORM 12b-25 |
|
NOTIFICATION OF LATE FILING
(Check one): |
x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR |
|
|
|
For Period Ended: December 31, 2016 |
|
|
|
o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR |
|
For the Transition Period Ended: ________ |
Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
N/A |
PART I - REGISTRANT INFORMATION
Net Medical Xpress Solutions, Inc. |
Full Name of Registrant |
|
N/A |
Former Name if Applicable |
|
5021 Indian School Road, Suite 100 |
Address of Principal Executive Office (Street and Number) |
|
Albuquerque, New Mexico 87110 |
City, State and Zip Code |
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
(a) |
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
x |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
(c) |
The accountants statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The Company is in the process of preparing and reviewing the financial and other information for its Form 10-K report for the annual period ended December 31, 2016, and does not expect the report will be finalized for filing by the prescribed due date without unreasonable effort or expense. The Company needs additional time to complete its financial statements, as well as to have the report reviewed by its accountants and attorneys. The Company undertakes the responsibility to file such report no later than fifteen days following the prescribed due date.
PART IV - OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification:
|
Richard F. Govatski |
|
(505) |
|
255-1999 |
|
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes x No o
(3)
Is it anticipated that any significant change in results of operation for the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes o No x
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
2
|
Net Medical Xpress Solutions, Inc. |
|
|
(Name of Registrant as Specified in Charter) |
|
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: |
March 31, 2017 |
|
By: |
/s/ Richard F. Govatski |
|
|
|
|
Richard F. Govatski Principal Executive Officer |
3
1 Year Net Medical Xpress Solut... (PK) Chart |
1 Month Net Medical Xpress Solut... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions